Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1015550 in progressive fibrosing interstitial lung disease
NL-OMON53889Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nerandomilast in progressive pulmonary fibrosis (PPF) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Absolute change from baseline in forced vital capacity at week 52. Started Mar 2023; status: recruiting.
02
Drugs
nerandomilast
03
Conditions
progressive pulmonary fibrosis (PPF)
Beyond the preview
Go deeper on NL-OMON53889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53889.